Biomarkers of aggressive pituitary adenomas
- Ozgur Mete1,2,3,
- Shereen Ezzat3,4,5 and
- Sylvia L Asa1,2,3
- 1Department of Pathology, University Health Network, 200 Elizabeth Street, 11th Floor, Toronto, Ontario, Canada M5G 2C4
2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
3Endocrine Oncology Site Group, Princess Margaret Hospital, Toronto, Ontario, Canada
4Department of Medicine, University Health Network, Toronto, Ontario, Canada
5Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- (Correspondence should be addressed to O Mete at Department of Pathology, University Health Network; Email: ozgur.mete2{at}uhn.ca)
Abstract
Pituitary adenomas exhibit a wide range of behaviors. The prediction of aggressive or malignant behavior in pituitary adenomas remains challenging; however, the utility of biomarkers is rapidly evolving. In this review, we discuss potential biomarkers as they relate to aggressive behavior in pituitary adenomas. While detailed histological subtyping remains the best independent predictor of aggressive behavior in the majority of cases, evidence suggests that the additional analyses of FGFR4, MMP, PTTG, Ki-67, p53, and deletions in chromosome 11 may contribute to decisions concerning management of aggressive pituitary adenomas.
- Revision received 12 July 2012
- Accepted 19 July 2012
- Made available online as an Accepted Preprint 19 July 2012
- © 2012 Society for Endocrinology
